For instance, repression of EIF4G2 is available to distinctively suppress the advancement of acute myeloid leukemia (AML) [20], diffuse large B-cell lymphoma (DLBCL) [21] and human osteosarcoma (HOS) [22]. Here, EIF4G2 is linked to acute myeloid leukemia.